I've been watching with some dismay as Thermo Fisher Scientific and Danaher have been bleeding for the last year, even as many pharma and biotech firms have been holding up fairly well (see MRK, BMY, CRSP…PFE is a big exception).
Is this still an extended COVID unwind, and did these firms really benefit that much from vaccine development and production? Or is something else at play here?
I tend to like these “picks and shovels” providers in healthcare and elsewhere, as their fortunes are not tied to any one drug or product working: they benefit as the whole industry grows and innovates.
I still believe in that broad thesis….just want to see where everyone stands on this healthcare segment, and where it sits relative to the trajectory of the broader industry right now.
Disclosure – Long term owner of TMO and DHR and have no plans to sell either of them. May buy more soon, actually.
Leave a Reply